Additional Dosage Strengths Of Vyvanse Approved By FDA

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for three additional dosage strengths for the attention deficit hyperactivity disorder (ADHD) treatment, VYVANSE™ ...

Write comment to this article:

Subject:

Name:

email or site:

Code: